PDYN and Alzheimer disease: Altogether, our results indicate that Aβ40 and dynorphins cross-interactions have potential pathophysiological implications in AD, which are worthy to explore further from the therapeutics and pathology perspectives, such as the basis for the design of inhibitory BigDyn-based peptides as therapeutic tools for the treatment of AD.